CN103705476B - Ilaprazole freeze-dried powder injection and preparation method thereof - Google Patents
Ilaprazole freeze-dried powder injection and preparation method thereof Download PDFInfo
- Publication number
- CN103705476B CN103705476B CN201410023774.6A CN201410023774A CN103705476B CN 103705476 B CN103705476 B CN 103705476B CN 201410023774 A CN201410023774 A CN 201410023774A CN 103705476 B CN103705476 B CN 103705476B
- Authority
- CN
- China
- Prior art keywords
- ilaprazole
- injectable powder
- injection
- water
- excipient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to an ilaprazole freeze-dried powder injection and a preparation method thereof. The ilaprazole freeze-dried powder injection provided by the invention comprises an active ingredient consisting of ilaprazole or a pharmaceutically acceptable salt thereof, a stabilizer, a solubilizer and/or an excipient, wherein the solubilizer is an inorganic base, and the inorganic base is one or two or a composition of more than two of sodium hydroxide, potassium hydroxide, sodium bicarbonate and potassium bicarbonate; the stabilizer is one or two or a combination of meglumine and hydroxypropyl-beta-cyclodextrin. According to the ilaprazole freeze-dried powder injection provided by the invention, through adding the stabilizer and the solubilizer, the problem of poor stability of ilaprazole is solved, the solubility of ilaprazole is increased, and the ilaprazole freeze-dried powder injection is stable in quality and high in effect taking speed.
Description
Technical field
The present invention relates to a kind of ilaprazole lyophilized injectable powder and preparation method thereof, be specifically related to the preparation of ilaprazole lyophilized injectable powder, prescription composition and preparation method, belong to field of medicaments.
Background technology
Ilaprazole (Ilaprazole), chemistry is by name: 5-(1 hydrogen-pyrroles-1-base)-2-[[(4-methoxyl group-3-methyl)-2-pyridine radicals]-methyl]-sulfinyl-1 hydrogen-benzimidazole.Ilaprazole (Ilaprazole, IY ~ 81149, OPRAH azoles, Yi Lila azoles) be a kind of medicine for the treatment of gastric ulcer sold by foreign Co., Ltd. of Korea S one and TAP drugmaker joint development, TAP drugmaker obtains the global development license except Korea S and China.Draw compared with azole drug with similar, the advantage of ilaprazole in the curative effect of safety and medicine is fairly obvious, curative effect is respectively 4 times of omeprazole, 6 times of lansoprazole, 8 times of pantoprazole, 4 times of rabeprazole, is the proton pump inhibitor that current gastric acid inhibitory effect is the strongest.
Calendar year 2001 December, beautiful pearl medicine limited company has signed " patent grant agreement " with foreign Co., Ltd. of Korea S one, obtain this product in inland of China, regional producing without competition, process and the power of sale such as Hong Kong, Macao etc.In December, 2007, the production and sales of " ilaprazole " (crude drug, traditional Chinese medicines accurate word H20070255) that approval bonded area, Li Zhu group subordinate exclusively-invested enterprise Zhuhai Li Da pharmaceutcal corporation, Ltd of State Food and Drug Administration declares and " ilaprazole enteric coatel tablets " (accurate word H20070256 of traditional Chinese medicines) that Li Zhu group beautiful pearl pharmacy head factory is declared.
Ilaprazole is alkalescence, in acid condition extremely unstable.In order to ensure ilaprazole take after pharmacologically active, what sell in the market is Ilaprazole enteric coated tablet.The enteric coated preparation of Chinese patent CN1184970C and CN1225240C respectively disclosed ilaprazole carries out enteric coating after ilaprazole being made micropill, is pressed into tablet afterwards again or in incapsulating, thus avoid ilaprazole by stomach acids destroy.Enteric coated preparation has delayed the initiation of ilaprazole to gastric acid, but is disadvantageous for needing treatment in time and removing painful patient rapidly.In addition, the coating material of enteric coated preparation and production technology directly can affect the oral absorption of ilaprazole, are thus necessary that developing a kind of injection solves this problem.Simultaneously ilaprazole is very poor at light, heat, water, oxygen, stable under acidic conditions, and Chinese patent CN102038648B discloses a kind of injection and preparation method for the treatment of peptic ulcer, and selected active component is Ilaprazole Sodium.Said preparation is made up of Ilaprazole Sodium, excipient, antioxidant and/or metal ion chelation agent, and wherein above-mentioned each constituent mass mark is than being ilaprazole 1 part, excipient 1 ~ 30,0 ~ 10 part, antioxidant and/or metal ion chelation agent 0 ~ 0.3 part.Effectively improve the problem of Ilaprazole Sodium stable under acidic conditions difference.But, add sodium thiosulfate in this patent of invention prescription, add the risk of medicine to blood vessel irritation.Simultaneously according to actual production, on the basis ensureing curative effect of medication, solubility and product appearance, the kind of adjuvant and consumption are more few better, are not only conducive to reducing corresponding toxic and side effects, increase Drug safety, can also save production cost.
Summary of the invention
The object of the invention is to, for above the deficiencies in the prior art, provide a kind of supplementary product kind and quantity few, blood vessel irritation risk is low, but stablize light, heat, water, oxygen, acid condition, dissolubility is good, and onset is ilaprazole and pharmaceutically acceptable lyophilized injectable powder thereof rapidly.The present inventor, by a large amount of tests, after adding solubilizing agent and making ilaprazole and inorganic base salify, reaches and dissolves completely; Ilaprazole is made to maintain the stability of medicine in drug solution preparing process by adding stabilizing agent; Use excipient as skeletal support, carry out lyophilizing to sample, obtained sample appearance is excellent, good stability, and speed of redissolving is fast; Simultaneously owing to using the adjuvant compared with the less kind of prior art and quantity, be not only conducive to reducing corresponding toxic and side effects, increase Drug safety, can also save production cost.
For realizing above goal of the invention, the present invention by the following technical solutions:
A kind of ilaprazole lyophilized injectable powder, it is by the raw material comprised by weight:
Obtain through following preparation technology:
(1) excipient, stabilizing agent are dissolved in partial syringe water, add solubilizing agent, be stirred to and dissolve completely, adjust ph to 9.0 ~ 12.0;
(2) ilaprazole is dissolved in step (1) gained solution, is stirred to and dissolves completely, adjust ph to 9.0 ~ 12.0, add remaining injection water;
(3) add medicinal carbon, membrane filtration, get fine straining liquid and carry out fill; Lyophilizing obtains.
Preferably, the weight proportion of each raw material of described injectable powder is:
Preferred, the weight proportion of each raw material of described injectable powder is:
Described injectable powder active component is ilaprazole or its pharmaceutically acceptable salt, and wherein ilaprazole pharmaceutically acceptable salt comprises sodium salt, potassium salt, preferably sodium salt.
Solubilizing agent in described injectable powder is inorganic base, described inorganic base solubilizing agent is selected from the compositions of one or more in sodium hydroxide, potassium hydroxide, sodium bicarbonate, potassium bicarbonate, potassium dihydrogen phosphate and sodium dihydrogen phosphate, and the inorganic base solubilizing agent in preferred described injectable powder is sodium hydroxide.
The stabilizing agent of described injectable powder is selected from one or both the compositions in meglumine, HP-β-CD; The stabilizing agent of preferred described injectable powder is meglumine.
The excipient of described injectable powder is selected from dextran, mannitol, trehalose, lactose and maltose; The excipient of preferred described injectable powder is dextran, such as Dextran-20 or Dextran 40.
On the other hand, present invention also offers the preparation method of above-mentioned ilaprazole lyophilized injectable powder, the preparation method of this injectable powder comprises the steps:
(1) take recipe quantity excipient, stabilizing agent in the water for injection of full dose 80%, be stirred to and dissolve completely, add recipe quantity solubilizing agent, be stirred to and dissolve completely, and adjust ph to 9.0 ~ 12.0.
(2) be dissolved in step (1) gained solution by recipe quantity ilaprazole, be stirred to and dissolve completely, adjust ph to 9.0 ~ 12.0, benefit adds to the full amount of water for injection; The pH of wherein said injectable powder is 9.0 ~ 12.0; Preferred pH is 10.5 ~ 11.5.
(3) in the medicinal liquid prepared, add the medicinal carbon of 0.01 ~ 1%, stirring at room temperature, with 0.22 μm of membrane filtration, get fine straining liquid and carry out fill; Wherein medicinal carbon consumption is 0.01 ~ 1% of medicinal liquid cumulative volume, and medicinal carbon consumption is preferably 0.1% of medicinal liquid cumulative volume.
(4) lyophilizing obtains.
Described step of freeze drying comprises:
Pre-freeze: by point medicinal liquid installed in-40 DEG C of insulation lyophilizing 5 hours;
Distillation: medicinal liquid good for pre-freeze is carried out evacuation ,-20 DEG C are incubated lyophilizing 18 hours;
Dry: the sample after distillation being terminated is warming up to 20 DEG C, heat preservation and dryness 3 hours.
Ilaprazole freeze-drying prods prepared by said method preferably seals preservation, and preferred vacuum is preserved.
Ilaprazole injectable powder in the present invention program has the following advantages:
(1) the present invention is under the prerequisite ensureing medicine solubility, curative effect and product appearance, and supplementary product kind and the consumption of selection are less, are not only conducive to reducing corresponding toxic and side effects, increases Drug safety, can also save production cost.
(2) under the prerequisite ensureing curative effect of medication and safety, in the present invention, the composition of preparation is simple, with low cost, and technique is simple, is convenient to large production operation.
(3) can be directly raw material with ilaprazole in the present invention, in preparation process, add suitable solubilizing agent inorganic base, make ilaprazole generate salt with inorganic base in drug solution preparing process, improve the dissolubility of medicine.
(4) in the ilaprazole injectable powder in the present invention, add stabilizing agent, decrease the generation of related substance in production process, decrease the untoward reaction of medicine, increase Drug safety.
(5) the ilaprazole injectable powder in the present invention, can be used for muscle or intravenous injection, and comparatively oral formulations absorbs rapidly, and simultaneously dry under vacuum conditions, the few moisture drying of oxygen content is thorough, protects product further, and stability is better more conducive to preserve.
(6) the ilaprazole injectable powder in the present invention, is applicable to the upper gastrointestinal hemorrhage that the treatment digestive ulcerative bleeding of medication alone or in combination and stress ulcer and prevention seriously disease should rise.For can not be oral patient with severe symptoms and stomach operation after the situation such as the upper gastrointestinal hemorrhage that causes evident in efficacy.
Detailed description of the invention
The present invention is described further in conjunction with example, but these examples are not limitation of the present invention.
Embodiment 1:
Prescription forms:
Preparation method:
(1) take recipe quantity Dextran-20 in the water for injection of full dose 80%, magnetic agitation is dissolved completely to Dextran-20, adds recipe quantity meglumine, adds sodium hydroxide after dissolving, and adjust ph to 9.0 ~ 12.0;
(2) be dissolved in by recipe quantity ilaprazole in step (1) gained solution, adjust ph to 9.0 ~ 12.0 after dissolving, benefit adds to the full amount of water for injection;
(3) in the medicinal liquid prepared, add the medicinal carbon of 0.1%, stirring at room temperature, with 0.22 μm of membrane filtration, get fine straining liquid and carry out fill;
(4) by medicinal liquid lyophilizing good for fill;
(5), after lyophilizing terminates, sample is jumped a queue outlet, rolls lid, to obtain final product.
Embodiment 2:
Prescription forms:
Preparation method:
(1) take recipe quantity Dextran-20 in the water for injection of full dose 80%, magnetic agitation is dissolved completely to Dextran-20, adds recipe quantity meglumine, adds sodium hydroxide after dissolving, and adjust ph to 9.0 ~ 12.0;
(2) be dissolved in by recipe quantity ilaprazole in step (1) gained solution, adjust ph to 9.0 ~ 12.0 after dissolving, benefit adds to the full amount of water for injection;
(3) in the medicinal liquid prepared, add the medicinal carbon of 0.1%, stirring at room temperature 15 minutes, with 0.22 μm of membrane filtration twice, get fine straining liquid and carry out fill;
(4) by medicinal liquid lyophilizing good for fill;
(5), after lyophilizing terminates, sample is jumped a queue outlet, rolls lid, to obtain final product.
Embodiment 3:
Prescription forms:
Preparation method:
(1) take recipe quantity Dextran 40 in the water for injection of full dose 80%, magnetic agitation, to dissolving completely, adds recipe quantity meglumine, adds sodium hydroxide after dissolving, and adjust ph to 9.0 ~ 12.0;
(2) be dissolved in by recipe quantity ilaprazole in step (1) gained solution, adjust ph to 9.0 ~ 12.0 after dissolving, benefit adds to the full amount of water for injection;
(3) in the medicinal liquid prepared, add the medicinal carbon of 0.1%, stirring at room temperature 15 minutes, with 0.22 μm of membrane filtration twice, get fine straining liquid and carry out fill;
(4) by medicinal liquid lyophilizing good for fill;
(5), after lyophilizing terminates, sample is jumped a queue outlet, rolls lid, to obtain final product.
Embodiment 4:
Prescription forms:
Preparation method:
(1) take recipe quantity Dextran 40 in the water for injection of full dose 80%, magnetic agitation is dissolved completely to Dextran 40, adds recipe quantity meglumine, adds sodium hydroxide after dissolving, and adjust ph to 9.0 ~ 12.0;
(2) be dissolved in by recipe quantity ilaprazole in step (1) gained solution, adjust ph to 9.0 ~ 12.0 after dissolving, benefit adds to the full amount of water for injection;
(3) in the medicinal liquid prepared, add the medicinal carbon of 0.1%, stirring at room temperature 15 minutes, with 0.22 μm of membrane filtration twice, get fine straining liquid and carry out fill;
(4) by medicinal liquid lyophilizing good for fill;
(5), after lyophilizing terminates, sample is jumped a queue outlet, rolls lid, to obtain final product.
Embodiment 5:
Prescription forms:
Preparation method:
(1) take recipe quantity mannitol in the water for injection of full dose 80%, magnetic agitation is dissolved completely to mannitol, adds recipe quantity meglumine, adds sodium hydroxide after dissolving, and adjust ph to 9.0 ~ 12.0;
(2) be dissolved in by recipe quantity ilaprazole in step (1) gained solution, adjust ph to 9.0 ~ 12.0 after dissolving, benefit adds to the full amount of water for injection;
(3) in the medicinal liquid prepared, add the medicinal carbon of 0.1%, stirring at room temperature 15 minutes, with 0.22 μm of membrane filtration twice, get fine straining liquid and carry out fill;
(4) by medicinal liquid lyophilizing good for fill;
(5), after lyophilizing terminates, sample is jumped a queue outlet, rolls lid, to obtain final product.
Embodiment 6:
Prescription forms:
Preparation method:
(1) take recipe quantity mannitol in the water for injection of full dose 80%, magnetic agitation is dissolved completely to mannitol, adds recipe quantity meglumine, adds recipe quantity meglumine, adds sodium hydroxide after dissolving, and adjust ph to 9.0 ~ 12.0;
(2) be dissolved in by recipe quantity ilaprazole in step (1) gained solution, adjust ph to 9.0 ~ 12.0 after dissolving, benefit adds to the full amount of water for injection;
(3) in the medicinal liquid prepared, add the medicinal carbon of 0.1%, stirring at room temperature 15 minutes, with 0.22 μm of membrane filtration twice, get fine straining liquid and carry out fill;
(4) by medicinal liquid lyophilizing good for fill;
(5), after lyophilizing terminates, sample is jumped a queue outlet, rolls lid, to obtain final product.
Embodiment 7:
Prescription forms:
2, preparation method:
(1) take recipe quantity lactose in the water for injection of full dose 80%, magnetic agitation is dissolved completely to lactose, adds recipe quantity meglumine, adds recipe quantity meglumine, adds sodium hydroxide after dissolving, and adjust ph to 9.0 ~ 12.0;
(2) be dissolved in by recipe quantity ilaprazole in step (1) gained solution, adjust ph to 9.0 ~ 12.0 after dissolving, benefit adds to the full amount of water for injection;
(3) in the medicinal liquid prepared, add the medicinal carbon of 0.1%, stirring at room temperature 15 minutes, with 0.22 μm of membrane filtration twice, get fine straining liquid and carry out fill;
(4) by medicinal liquid lyophilizing good for fill;
(5), after lyophilizing terminates, sample is jumped a queue outlet, rolls lid, to obtain final product.
Embodiment 8:
Prescription forms:
Preparation method:
(1) take recipe quantity lactose in the water for injection of full dose 80%, magnetic agitation is dissolved completely to lactose, adds recipe quantity HP-β-CD, adds sodium hydroxide after dissolving, and adjust ph to 9.0 ~ 12.0;
(2) be dissolved in by recipe quantity ilaprazole in step (1) gained solution, adjust ph to 9.0 ~ 12.0 after dissolving, benefit adds to the full amount of water for injection;
(3) in the medicinal liquid prepared, add the medicinal carbon of 0.1%, stirring at room temperature 15 minutes, with 0.22 μm of membrane filtration twice, get fine straining liquid and carry out fill;
(4) by medicinal liquid lyophilizing good for fill;
(5), after lyophilizing terminates, sample is jumped a queue outlet, rolls lid, to obtain final product.
Embodiment 9:
Prescription forms:
Preparation method:
(1) take recipe quantity trehalose in the water for injection of full dose 80%, magnetic agitation is dissolved completely to trehalose, adds recipe quantity HP-β-CD, adds sodium hydroxide after dissolving, and adjust ph to 9.0 ~ 12.0;
(2) be dissolved in by recipe quantity ilaprazole in step (1) gained solution, adjust ph to 9.0 ~ 12.0 after dissolving, benefit adds to the full amount of water for injection;
(3) in the medicinal liquid prepared, add the medicinal carbon of 0.1%, stirring at room temperature 15 minutes, with 0.22 μm of membrane filtration twice, get fine straining liquid and carry out fill;
(4) by medicinal liquid lyophilizing good for fill;
(5), after lyophilizing terminates, sample is jumped a queue outlet, rolls lid, to obtain final product.
Comparative example 1
Prescription forms:
Preparation technology: according to patent " injectable powder for the treatment of peptic ulcer and preparation method thereof ", publication number is CN102038648A, and the preparation method of the embodiment 2 of announcement prepares sample.
Comparative example 2 (without stabilizing agent)
Prescription forms:
Preparation method:
(1) take recipe quantity trehalose in the water for injection of full dose 80%, magnetic agitation is dissolved completely to trehalose, and back end hydrogenation sodium oxide regulates pH9.0 ~ 12.0;
(2) be dissolved in by recipe quantity ilaprazole in step (1) gained solution, dissolve back end hydrogenation sodium oxide and regulate pH9.0 ~ 12.0, benefit adds to the full amount of water for injection;
(3) in the medicinal liquid prepared, add the medicinal carbon of 0.1%, stirring at room temperature 15 minutes, with 0.22 μm of membrane filtration twice, get fine straining liquid and carry out fill;
(4) by medicinal liquid lyophilizing good for fill;
(5) after lyophilizing terminates, sample is jumped a queue outlet, rolls lid, product inspection, packaging, warehouse-in.
Comparative example 3 (without stabilizing agent)
Prescription forms:
Preparation method:
(1) take recipe quantity mannitol in the water for injection of full dose 80%, magnetic agitation is dissolved completely to mannitol, and back end hydrogenation sodium oxide regulates pH9.0 ~ 12.0;
(2) be dissolved in by recipe quantity ilaprazole in step (1) gained solution, dissolve back end hydrogenation sodium oxide and regulate pH9.0 ~ 12.0, benefit adds to the full amount of water for injection;
(3) in the medicinal liquid prepared, add the medicinal carbon of 0.1%, stirring at room temperature 15 minutes, with 0.22 μm of membrane filtration twice, get fine straining liquid and carry out fill;
(4) by medicinal liquid lyophilizing good for fill;
(5) after lyophilizing terminates, sample is jumped a queue outlet, rolls lid, product inspection, packaging, warehouse-in.
Above embodiment and comparative example are carried out study on the stability, and result of the test is as follows:
1, influence factor's test
Sample is carried out influence factor's test, sample appearance shape before and after determination influences Factor Experiment, content, related substance situation of change.
By the ilaprazole lyophilized injectable powder sample prepared by above-described embodiment 1 ~ 11 prescription and comparative example 1-3 prescription, be placed in respectively 4500lx illumination, 40 DEG C, 60 DEG C carry out influence factor's experimental box and investigate, respectively at 5 days and 10 days sample for reference face shapings, content, related substance, and contrast with 0 day data, concrete data are in table 1, table 2, table 3.
Table 1 illumination experiment result:
Table 2 influence factor 40 DEG C
Table 3 influence factor 60 DEG C:
Conclusion:
Through factors influencing, adopt ilaprazole lyophilized injectable powder sample prepared by this patent, content 95% ~ 110%, related substance 0.35% ~ 0.45% is all better than comparative example.Can reach a conclusion, adding stabilizing agent in prescription can play good Stabilization to product, and sample is in illumination, and hot conditions stability inferior is apparently higher than comparative example.
Claims (5)
1. an ilaprazole lyophilized injectable powder, it obtains by comprising following raw material by weight:
Ilaprazole 1 part
Solubilizing agent 0.1 ~ 2 part
Stabilizing agent 0.1 ~ 5 part
Excipient 0.1 ~ 10 part
Water for injection 100 parts
Described solubilizing agent is sodium hydroxide, potassium hydroxide, sodium bicarbonate, potassium bicarbonate, potassium dihydrogen phosphate, the compositions of one or more in sodium dihydrogen phosphate;
Described stabilizing agent is HP-β-CD;
Described excipient is selected from the compositions of one or more in dextran, mannitol, trehalose, lactose and maltose.
2. injectable powder according to claim 1, it obtains by comprising following raw material by weight:
Ilaprazole 1 part
Solubilizing agent 0.1 ~ 1 part
Stabilizing agent 0.1 ~ 2 part
Excipient 0.1 ~ 5 part
Water for injection 100 parts.
3. injectable powder according to claim 2, is characterized in that described solubilizing agent is sodium hydroxide.
4. injectable powder according to claim 3, wherein said excipient is dextran.
5. prepare the method for injectable powder according to claim 1, it is characterized in that comprising the following steps:
(1) excipient, stabilizing agent are dissolved in partial syringe water, add solubilizing agent, be stirred to and dissolve completely, adjust ph to 9.0 ~ 12.0;
(2) ilaprazole is dissolved in step (1) gained solution, is stirred to and dissolves completely, adjust ph to 9.0 ~ 12.0, add remaining injection water;
(3) add medicinal carbon, membrane filtration, get fine straining liquid and carry out fill; Lyophilizing obtains.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410023774.6A CN103705476B (en) | 2014-01-20 | 2014-01-20 | Ilaprazole freeze-dried powder injection and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410023774.6A CN103705476B (en) | 2014-01-20 | 2014-01-20 | Ilaprazole freeze-dried powder injection and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103705476A CN103705476A (en) | 2014-04-09 |
| CN103705476B true CN103705476B (en) | 2015-02-25 |
Family
ID=50399071
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410023774.6A Active CN103705476B (en) | 2014-01-20 | 2014-01-20 | Ilaprazole freeze-dried powder injection and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103705476B (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104922080A (en) * | 2015-05-26 | 2015-09-23 | 苗怡文 | Pharmaceutical ilaprazole sodium freeze-dried powder injection composition for treating digestive system diseases |
| CN105769778B (en) * | 2016-04-02 | 2018-08-10 | 丽珠医药集团股份有限公司 | A kind of Iprazole sodium injection and preparation method thereof |
| CN105769777B (en) * | 2016-04-02 | 2018-08-10 | 丽珠医药集团股份有限公司 | A kind of Iprazole sodium freeze-dried powder injection |
| CN107595786A (en) * | 2017-09-25 | 2018-01-19 | 丽珠医药集团股份有限公司 | Dextrorotation Iprazole sodium injection containing dextran and preparation method thereof |
| CN107638392A (en) * | 2017-09-25 | 2018-01-30 | 丽珠医药集团股份有限公司 | Dextrorotation Iprazole sodium injection containing trehalose and preparation method thereof |
| CN107468659A (en) * | 2017-09-26 | 2017-12-15 | 丽珠医药集团股份有限公司 | A kind of lactinated powder-injection and preparation method thereof |
| CN110118831A (en) * | 2018-04-23 | 2019-08-13 | 丽珠医药集团股份有限公司 | A method of detection Iprazole Drug-related |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102038648B (en) * | 2009-10-23 | 2012-07-25 | 丽珠医药集团股份有限公司 | Powder injection for treating peptic ulcers and preparation method thereof |
| CN101804035B (en) * | 2010-04-22 | 2012-01-11 | 江苏济川制药有限公司 | Lansoprazole preparation for injection and preparation method thereof |
-
2014
- 2014-01-20 CN CN201410023774.6A patent/CN103705476B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN103705476A (en) | 2014-04-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103705476B (en) | Ilaprazole freeze-dried powder injection and preparation method thereof | |
| CN102038648B (en) | Powder injection for treating peptic ulcers and preparation method thereof | |
| CN102100671B (en) | Method for preparing esomeprazole enteric capsules | |
| CN101716176A (en) | R-lansoprazole for injection and preparation method thereof | |
| CN104023715B (en) | The side effect depressant of inhibitors of kinases | |
| CN112789059A (en) | Use of amino acid nutrients and pharmaceutical compositions containing same | |
| RU2017136992A (en) | PHARMACEUTICAL COMPOSITION CONTAINING SILIBIN AND VITAMIN E | |
| CN104706604A (en) | Perampanel freeze-dried oral disintegrating tablet and preparation method thereof | |
| EP3384929B1 (en) | Method for using small molecule compounds to induce human tumor cells to be directly reprogrammed into non-oncogenic cells | |
| CN103961322B (en) | A kind of injection Dexlansoprazole freeze-dried composition and preparation method thereof | |
| CN101229162A (en) | Freeze-dried powder injection containing dextrogyrate rabeprazole and salts thereof, preparing technology thereof | |
| CN102319223B (en) | Esomeprazole freeze-dried preparation and preparation method thereof | |
| JP5476782B2 (en) | Method for producing arginine-containing tablets | |
| CN106692081B (en) | A kind of freeze-dried powder injection of pantoprazole sodium and preparation method | |
| CN105125507B (en) | A kind of Esomeprazole sodium injection freezes compound powder and preparation method thereof | |
| TWI725191B (en) | Physiologically balanced injectable formulations of fosnetupitant | |
| CN106667944A (en) | Sustained release preparation containing prostaglandin drugs | |
| JP2010270111A (en) | Arginine-containing tablet | |
| CN101890015B (en) | Liposome injection of pharmaceutical composition comprising piperacillin sodium and tazobactam sodium | |
| CN110339169A (en) | Coat nano vesicle preparations and its application of vitamin D and vitamin K | |
| CN105853377B (en) | A kind of sodium rebeilazole for injection use preparation and preparation method thereof | |
| CN104490800B (en) | A kind of good fortune department Fluconazole freezes compound powder and preparation method thereof | |
| CN105395490B (en) | A kind of freeze-dried powder of sodium pharmaceutical composition containing dextral-rabeprazole and preparation method thereof | |
| CN104490802A (en) | Salidroside enteric-coated tablets and preparation method thereof | |
| JP6732351B1 (en) | Isoquercitrin composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CP03 | Change of name, title or address |
Address after: 750002 the Ningxia Hui Autonomous Region street, Jinfeng District, Yinchuan City Fu Ning Lane No. 57 Patentee after: Ningxia Kang Ya pharmaceutical Limited by Share Ltd Address before: 750002 No. 6 road, hi tech Industrial Development Zone, the Ningxia Hui Autonomous Region, Yinchuan Patentee before: Kangya Pharmaceutical Industry Co., Ltd., Ningxia |
|
| CP03 | Change of name, title or address | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20210126 Address after: 215123 unit e347, A1 / F, biomedical industrial park, 218 Xinghu street, Suzhou Industrial Park, Suzhou area, China (Jiangsu) pilot Free Trade Zone, Suzhou City, Jiangsu Province Patentee after: Suzhou Yutai Pharmaceutical Technology Co.,Ltd. Address before: 750002 57 Fu'an West Lane, Ning'an street, Jinfeng District, Yinchuan City, Ningxia Hui Autonomous Region Patentee before: KANGYA OF NINGXIA PHARMACEUTICAL Co.,Ltd. |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20210323 Address after: 150000 Beijing Road, Limin Development Zone, Hulan District, Harbin City, Heilongjiang Province Patentee after: HARBIN MEDISAN PHARMACEUTICAL Co.,Ltd. Address before: 215123 unit e347, A1 / F, biomedical industrial park, 218 Xinghu street, Suzhou Industrial Park, Suzhou area, China (Jiangsu) pilot Free Trade Zone, Suzhou City, Jiangsu Province Patentee before: Suzhou Yutai Pharmaceutical Technology Co.,Ltd. |
|
| TR01 | Transfer of patent right |